1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFoundation Grants is sponsored by Cumming Global Centre for Pandemic Therapeutics, Peter Doherty Institute for Infection and Immunity. Globally open research grants for projects developing novel therapeutics for pathogens of pandemic potential, emphasizing adaptable treatment platforms rather than single‑pathogen approaches. [1]
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Investigators worldwide based at eligible research institutions, including universities and affiliated research institutes; projects must focus on therapeutics for pathogens of pandemic potential (clinical trials and si…. Confirm the full requirements in the official notice before applying.
The current listing shows up to AU$200,000 per year for 3 years (up to AU$600,000). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Foundation Grants is funded by Cumming Global Centre for Pandemic Therapeutics, Peter Doherty Institute for Infection and Immunity. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article